Stanniocalcin-1 protein expression profile and mechanisms in proliferation and cell death pathways in prostate cancer
| Autor: | Fernanda Bordignon Nunes, Ilma Simoni Brum, R. Zhao, Andressa Schneiders Santos, Lucia Maria Kliemann, João C.R. Cardoso, Gisele Branchini, Bruna Pasqualotto Costa, Adelino V.M. Canario, Rute C. Félix, Vanessa Schein |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine Programmed cell death Cell cycle checkpoint Stanniocalcin-1 Prostatic Hyperplasia Apoptosis 030209 endocrinology & metabolism Biochemistry 03 medical and health sciences Prostate cancer 0302 clinical medicine Endocrinology Prostate Cell Line Tumor Biomarkers Tumor medicine Humans STC1 Gleason score Molecular Biology Cell Proliferation Glycoproteins Cell growth business.industry Colforsin Prostatic Neoplasms Cell Cycle Checkpoints Hyperplasia medicine.disease Up-Regulation 030104 developmental biology medicine.anatomical_structure PC-3 Cells Disease Progression Cancer research Tumour development business Prostatic neoplasm |
| Zdroj: | Repositório Científico de Acesso Aberto de Portugal Repositório Científico de Acesso Aberto de Portugal (RCAAP) instacron:RCAAP |
| Popis: | Prostate cancer (PCa) is one of the most prevalent male tumours. Stanniocalcin-1 (STC1) is a glycoprotein and, although the role of STC1 in human cancer is poorly understood, it is suggested to be involved in the development and progression of different neoplasms. This study investigated the protein expression profile of STC1 in PCa and benign prostatic hyperplasia (BPH) samples and STC1 signalling during cell proliferation and cell death in vitro using cell lines. We found higher levels of STC1 in PCa when compared to BPH tissue and that STC1 inhibited forskolin stimulation of cAMP in PC-3 cells. A monoclonal antibody against STC1 was effective in reducing cell proliferation, in promoting cell cycle arrest, and in increasing apoptosis in the same cells. Since STC1 acts as a regulator of prostatic tissue signalling, we suggest that this protein is a novel candidate biomarker for prostate tumour clinical progression and a potential therapeutic target. info:eu-repo/semantics/publishedVersion |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|